Enervit
ISIN: IT0004356751 | Ticker: ENV | LEI: 8156002B06C3A4C0F436
Country: Italy
Positive nutrition is part of our DNA. It has always guided our advancements in field research and deepened our passion for innovation. It drives us to study the lifestyles and eating habits of the populations that have learned to live better and longer. It allows us to anticipate the nutrition of the future. It leads us to formulate and produce ideal nutrition and supplement solutions for those who practice sports, those who are health-conscious and those who want to stay in shape. All this with a specific objective: to help everyone improve the quality of their life.
For over 40 years, a passion for sports nutrition has driven our scientific research. Day after day, thanks to this unique experience we invent, test, develop and produce high-quality functional foods and innovative supplements. Ours is a fully in-house approach to satisfying the nutritional needs of those who practice sports, those who are health-conscious and those who want to stay in shape.
1954
Served areaWorldwide
Headcount232
HeadquartersViale Achille Papa 30, 20149 Milano – Italy
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Land | N/A | 207,243.00 | 207,243.00 | 207,243.00 |
| Buildings | N/A | 3,670,780.00 | 3,392,353.00 | 3,160,431.00 |
| Fixtures And Fittings | N/A | 607,355.00 | 580,409.00 | 537,446.00 |
| Construction In Progress | N/A | 84,127.00 | 129,902.00 | 288,388.00 |
| Other Property Plant And Equipment | N/A | 238,710.00 | 181,262.00 | 195,651.00 |
| Brand Names | N/A | 60,000.00 | 60,000.00 | 60,000.00 |
| Copyrights Patents And Other Industrial Property Rights Service And Operating Rights | N/A | 504,910.00 | 366,866.00 | 733,761.00 |
| Recipes Formulae Models Designs And Prototypes | N/A | 990,041.00 | 980,362.00 | 939,648.00 |
| Intangible Assets Under Development | N/A | 390,898.00 | 604,265.00 | 223,644.00 |
| Other Intangible Assets | N/A | 24,686.00 | 20,059.00 | 15,432.00 |
| Trade And Other Current Receivables Due From Related Parties | N/A | 535,252.00 | 701,382.00 | 965,976.00 |
| Cash and cash equivalents | 2,379,133.00 | 13,948,134.00 | 18,504,912.00 | 16,757,494.00 |
| Statutory Reserve | N/A | 1,236,405.00 | 1,236,405.00 | 1,413,917.00 |
| Capital Reserve | N/A | 46,481.00 | 46,481.00 | 46,481.00 |
| Noncurrent Derivative Financial Liabilities | N/A | 216,682.00 | 62,290.00 | 0.00 |
| Longterm Borrowings | N/A | 20,968,705.00 | 16,782,984.00 | 12,799,430.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue From Contracts With Customers | 51,836,625.00 | 64,749,977.00 | 76,304,783.00 |
| Profit (loss) | -1,898,499.00 | 3,595,539.00 | 4,164,907.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -1,898,499.00 | 3,595,539.00 | 4,164,907.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 11,569,002.00 | 4,556,778.00 | -1,747,418.00 |
| Cash and cash equivalents | 2,379,133.00 | 13,948,134.00 | 18,504,912.00 | 16,757,494.00 |
Please note that some sums might not add up.
IT0004356751
LEI8156002B06C3A4C0F436
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.